Lytgobi® – targeted therapy for genetically altered cholangiocarcinoma

Photo of author
Written By Kampretz Bianca

Lorem ipsum dolor sit amet consectetur pulvinar ligula augue quis venenatis. 

Candidate Galeno 2024

Futibatinib (Lytgobi®) from Taiho Oncology Europe is a novel tyrosine kinase inhibitor indicated for the second-line treatment of locally advanced or metastatic cholangiocarcinoma with genetically altered fibroblast growth factor receptor 2 (FGFR2).

Source link

Norovirus: what are the symptoms and how to protect yourself?

Big Change for Tourists – This Affects Almost Everyone

Leave a Comment

RSS Error: A feed could not be found at `https://hallocine.app/feed`; the status code is `404` and content-type is `text/html`

Contact Us

Contact Us

@2024 Healthyfoodideas

Privacy Policy Terms of Service
cal cal cal cal cal cal cal cal cal cal cal cal cal cal cal cal cal cal cal cal cal cal cal cal cal cal cal cal cal cal cal cal cal cal cal cal cal cal